Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sunitinib vs. Interferon-
in Patients with Metastatic Renal Carcinoma
Patients treated with sunitinib had a median progression-free survival that was significantly longer than that of patients who received interferon.
Sign In
Don't yet have a username or password?
Register now for
Journal Watch e-mail alerts and unlimited online
access to articles 6 months after publication.
Subscribe now for
Full, immediate online access to all Journal Watch content and services.
Already a subscriber? Activate your subscription to receive full online access.
Get full site access with a 7-day site pass for $19